Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Elfabrio® (pegunigalsidase alfa-iwxj) – New drug approval
May 10, 2023 - Chiesi Global Rare Diseases and Protalix BioTherapeutics announced the FDA approval of Elfabrio (pegunigalsidase alfa-iwxj), for the treatment of adults with confirmed Fabry disease.
